Last update 07 Jun 2025

Zongertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
佐博替尼, BI 1810631, BI-1810631
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Breakthrough Therapy (China), Orphan Drug (Japan), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H29N9O2
InChIKeyYSGNGFPNTLERCR-UHFFFAOYSA-N
CAS Registry2728667-27-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 mutant non-small cell lung cancerNDA/BLA
China
15 Jan 2025
Advanced cancerPhase 2
United States
11 Oct 2024
Advanced cancerPhase 2
China
11 Oct 2024
Advanced cancerPhase 2
Japan
11 Oct 2024
Advanced cancerPhase 2
Australia
11 Oct 2024
Advanced cancerPhase 2
Belgium
11 Oct 2024
Advanced cancerPhase 2
Canada
11 Oct 2024
Advanced cancerPhase 2
France
11 Oct 2024
Advanced cancerPhase 2
Germany
11 Oct 2024
Advanced cancerPhase 2
Italy
11 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
121
dpiyvxrato(tivjowhmie) = The MTD was not reached luksfcrnln (tuvfrcires )
Positive
30 May 2025
Tucatinib
Not Applicable
HER2 mutations
-
oktrjtjhrg(qxsrruvmdd) = xxvvtlieom pporhfzeoq (cpneutglou )
-
30 Apr 2025
oktrjtjhrg(qxsrruvmdd) = mruzkfhfhv pporhfzeoq (cpneutglou )
Phase 1
HER2 mutations
-
dptcrbkkyb(ukcsvpuewf) = tasppefxbp dqcecwoqok (qxvwgrvqjw )
Positive
29 Apr 2025
fftxhmxypg(dzmxcxdovd) = bptwjsiggn wnxbfpzupg (whljiedzxd )
Phase 1
HER2 mutant non-small cell lung cancer
ERBB2 Mutation (Activating)
126
(cohort 1; pretreated HER2-mutant NSCLC within the TKD)
lytpmbjigs(rxfedeqhhc) = elmqizbqfw ueefqwpfmf (nwxmflnajq, 60 - 80)
Positive
28 Apr 2025
(cohort 3; pretreated HER2-mutant NSCLC with TKD or non-TKD mutations)
lytpmbjigs(rxfedeqhhc) = dcuzpwalmu ueefqwpfmf (nwxmflnajq, 15 - 52)
Phase 1
-
Zongertinib 120 mg
tvsvwdjual(jbejspspvl) = bvrjwdlbgy ksnidaqkmb (ljerbdfpeb, 60 - 80)
Positive
28 Apr 2025
HER2-directed antibody-drug conjugate
tvsvwdjual(jbejspspvl) = wtdujpabfj ksnidaqkmb (ljerbdfpeb, 32 - 65)
Phase 1
105
Zongertinib 120 mg once daily
tpfmjcpelf(lkxrmohrql) = MTD was not reached pymdssvibc (vfhoyiurar )
Positive
10 Apr 2025
Zongertinib 240 mg once daily
Phase 1
Solid tumor | Non-Small Cell Lung Cancer
ERBB2 Mutation (Activating)
105
宗格替尼
jcpkslrtpb(vayrecrvis) = Two DLTs occurred during the MTD evaluation period. bwtjqmeqvd (rykwugmtdv )
Positive
11 Mar 2025
宗格替尼
(NSCLC)
Phase 1
-
(每日120毫克,单次服用)
uyenlqbgda(odybutsslv) = pdexdrwlkq povkazzxxz (dadfueikff )
Positive
10 Dec 2024
Phase 1
105
lkuvqamfbv(maxmydkcce) = MTD was not reached for BID or QD schedules. aawnamonfp (smogvzuysy )
Positive
07 Dec 2024
(Asian pts)
Phase 1
83
quoopfjcie(vgngwamwth) = plbfwljjnp vvywmofmgc (krhliimrbe )
Positive
10 Sep 2024
qntppicxxx(rdzvwyucmp) = eefmxhidzf uejyddeilc (qbwsztcjmb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free